On July 1, 2010, the European General Court rendered its judgment in the AstraZeneca case, dismissing for the most part AstraZeneca’s appeal against the Commission’s infringement decision of June 2005.  In that decision, the Commission had found AstraZeneca’s Losec to be dominant in the market for proton pump inhibitors, a type of medicine used for…